Annex

United Kingdom

The purity indicated in this column was the minimum degree of purity of the active substance used for the evaluation made in accordance with Article 89(1) of Regulation (EU) No 528/2012. The active substance in the product placed on the market can be of equal or different purity if it has been proven technically equivalent with the evaluated active substance.
Common Name	IUPAC NameIdentification Numbers	Minimum degree of purity of the active substance^f1	Date of approval	Expiry date of approval	Product type	Specific conditions
Bacillus amyloliquefaciens strain ISB06	Not applicable	No relevant impurities	1 January 2018	31 December 2027	3	The authorisations of biocidal products are subject to the following conditions: 1.. The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any use covered by an application for authorisation, but not addressed in the Union level risk assessment of the active substance. 2.. In view of the risks identified for the uses assessed, the product assessment shall pay particular attention to professional users.

The purity indicated in this column was the minimum degree of purity of the active substance used for the evaluation made in accordance with Article 89(1) of Regulation (EU) No 528/2012. The active substance in the product placed on the market can be of equal or different purity if it has been proven technically equivalent with the evaluated active substance.

Common Name

IUPAC NameIdentification Numbers

Minimum degree of purity of the active substance^f1

Date of approval

Expiry date of approval

Product type

Specific conditions

Bacillus amyloliquefaciens strain ISB06

Not applicable

No relevant impurities

1 January 2018

31 December 2027

The authorisations of biocidal products are subject to the following conditions:

1..

The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any use covered by an application for authorisation, but not addressed in the Union level risk assessment of the active substance.
2..

In view of the risks identified for the uses assessed, the product assessment shall pay particular attention to professional users.

Annotations

Footnotes

f1: The purity indicated in this column was the minimum degree of purity of the active substance used for the evaluation made in accordance with Article 89(1) of Regulation (EU) No 528/2012. The active substance in the product placed on the market can be of equal or different purity if it has been proven technically equivalent with the evaluated active substance.